Skip to content

A study on strategies for the prevention and treatment of metabolic syndrome in Chinese medicine and the preliminary construction of a predictive model for cardiovascular disease risk - a prospective cohort study

A study on strategies for the prevention and treatment of metabolic syndrome in Chinese medicine and the preliminary construction of a predictive model for cardiovascular disease risk - a prospective cohort study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000037
Enrollment
Unknown
Registered
2022-06-20
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome

Interventions

Combined Chinese and Western Medicine Group:Based on the standard treatment of Western medicine, the basic formula is selected according to the different types of evidence and added with the Tongluo g

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) age 30-80 years, gender not limited; (2) meet the diagnostic criteria for metabolic syndrome and any of the above TCM evidence types; (3) have good compliance; (4) sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Exclusion of other primary diseases causing (chronic kidney disease, chronic liver disease, hypothyroidism) abnormalities in blood glucose, lipids and blood pressure. (2) Combination of severe cardiovascular and cerebrovascular diseases, such as heart failure, severe hypertension, cerebral haemorrhage, etc. (3) Combined with severe liver function abnormalities (ALT or AST reaching more than 3 times the upper limit of normal), endocrine diseases, malignant tumours and autoimmune diseases (4) Women who are pregnant, preparing for pregnancy or breastfeeding. (5) Allergy and hypersensitivity to the components of the drug used in this study. (6) Those who are participating in other clinical trials or have participated in clinical trials of other drugs for less than 1 month.

Design outcomes

Primary

MeasureTime frame
Lipid Indicators;Waist Circumference;Blood glucose indicators;Blood Pressure;

Secondary

MeasureTime frame
Stool Routine;Blood count;Obesity Indicators;Urine Routine;Complete Biochemistry;Abdominal ultrasound;Carotid ultrasound;Cardiac ultrasound;

Countries

China

Contacts

Public ContactQingqiao Song

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Songqq985@126.com13911873540

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026